Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 20/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 16/20 | 0.53 |
| ▸ | PTPRC | P08575 | 15/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558341 | 0.90 | PTPN1 (0.67) | PTPN1PTPN2PTPRC | |
| SCHEMBL7561036 | 0.89 | PTPN1 (0.58) | PTPN1PTPN2PTPRC | |
| SCHEMBL7564653 | 0.82 | PTPN1 (0.54) | PTPN1PTPN2PTPRC | |
| SCHEMBL7526513 | 0.81 | PTPN1 (0.77) | PTPN1PTPN2PTPRC | |
| SCHEMBL7526715 | 0.80 | PTPN1 (0.80) | PTPN1PTPN2PTPRC | |
| SCHEMBL7527918 | 0.80 | PTPN1 (0.71) | PTPN1PTPN2PTPRC | |
| SCHEMBL7527026 | 0.79 | PTPN1 (0.83) | PTPN1PTPN2PTPRC | |
| SCHEMBL7561026 | 0.78 | PTPN1 (0.75) | PTPN1PTPN2PTPRC | |
| SCHEMBL7583197 | 0.77 | PTPN1 (0.54) | PTPN1PTPN2PTPRC | |
| SCHEMBL6944264 | 0.77 | PTPN1 (0.83) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486141-B2 | TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | claimed |
| EP-1244677-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | claimed |
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | claimed |
| WO-2001046203-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | claimed |
| US-6486141-B2 | TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| EP-1244677-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | disclosed |
| WO-2001046203-A1 | PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052346-A1 | Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PTPRO, PPM1B, PTPA | PTPN1 15/4885PTPN2 28/4885PTPRC 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.